Rucaparib in recurrent ovarian cancer. Real-world experience from the rucaparib early access programme in Spain - A GEICO study

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Yubero, Alfonso
  • dc.contributor.author Taus García, Álvaro
  • dc.contributor.author González Martín, Antonio
  • dc.date.accessioned 2023-02-24T07:44:44Z
  • dc.date.available 2023-02-24T07:44:44Z
  • dc.date.issued 2022
  • dc.description.abstract Background: rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well as for patients with BRCA-mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives. Methods: in this observational, retrospective study we analysed the efficacy and safety of rucaparib within the RAP in Spain. Hospitals associated with the Spanish Ovarian Cancer Research Group (GEICO) recruited patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated with rucaparib 600 mg twice daily as maintenance or treatment (Pt-S/Pt-R) in the RAP. Baseline characteristics, efficacy, and safety data were collected. Results: between July 2020 and February 2021, 51 patients treated in 22 hospitals in the RAP were included in the study. Eighteen patients with a median of 3 (range, 1-6) prior treatment lines received rucaparib as maintenance; median progression-free survival (PFS) for this group was 9.1 months (95% confidence interval [CI], 4.2-11.6 months). Among 33 patients (median 5 [range, 1-9] prior treatment lines) who received rucaparib as treatment, 7 and 26 patients had Pt-S and Pt-R disease, respectively. Median PFS was 10.6 months (95% CI, 2.5 months-not reached) in the Pt-S group and 2.2 months (95% CI, 1.1-3.2 months) in the Pt-R group. Grade ≥ 3 treatment-emergent adverse events were reported in 39% of all patients, the most common being anaemia (12% and 15% in the maintenance and treatment groups, respectively). At data cut-off, 5 patients remained on treatment. Conclusion: efficacy results in these heavily pre-treated patients were similar to those from previous trials. The safety profile of rucaparib in real life was predictable and manageable.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, et al. Rucaparib in recurrent ovarian cancer. Real-world experience from the rucaparib early access programme in Spain - A GEICO study. BMC Cancer. 2022 Nov 8; 22(1): 1150. DOI: 10.1186/s12885-022-10191-5
  • dc.identifier.doi http://dx.doi.org/10.1186/s12885-022-10191-5
  • dc.identifier.issn 1471-2407
  • dc.identifier.uri http://hdl.handle.net/10230/55922
  • dc.language.iso eng
  • dc.publisher BioMed Central
  • dc.rights Copyright © Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, et al. 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by/4.0/
  • dc.subject.keyword Maintenance
  • dc.subject.keyword PARP inhibitor
  • dc.subject.keyword Recurrent ovarian cancer
  • dc.subject.keyword Rucaparib
  • dc.subject.keyword Treatment
  • dc.title Rucaparib in recurrent ovarian cancer. Real-world experience from the rucaparib early access programme in Spain - A GEICO study
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)